Travere Therapeutics, Inc. (TVTX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $53.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality.
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved FILSPARI (sparsentan) for IgAN and a supplemental NDA under review for FSGS (PDUFA April 13, 2026), plus pegtibatinase in pivotal Phase 3 for homocystinuria.... Read more
Sell if holding. Engine safety override at $53.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Travere Therapeutics, Inc.
Latest news
- NEWS Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70 — benzinga Jun 15, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65 — benzinga Jun 12, 2026 positive
- NEWS Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In T — benzinga Jun 4, 2026 positive
- NEWS Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62 — benzinga Jun 3, 2026 positive
- NEWS Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target — benzinga Jun 3, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductFILSPARI10-K Item 1A: 'our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI'
- HIGHSuppliersole source suppliers for FILSPARI and Thiola10-K Item 1A: 'rely on third-party manufacturers who are currently sole source suppliers for manufacturing of FILSPARI and Thiola'
- HIGHpipelinesparsentan FSGS sNDA10-K Item 1A: 'The sNDA remains under review by the FDA with a PDUFA target action date of April 13, 2026.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $53.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Prior stop was $49.77. Score 5.9/10, moderate confidence.
Take-profit target: $52.72 (-1.5% upside). Prior stop was $49.77. Stop-loss: $49.77.
Concentration risk — Product: FILSPARI; Concentration risk — Supplier: sole source suppliers for FILSPARI and Thiola; Target reached (-8.7% upside).
Travere Therapeutics, Inc. trades at a P/E of N/A (forward 10.6). TrendMatrix value score: 6.3/10. Verdict: Sell.
21 analysts cover TVTX with a consensus score of 4.3/5. Average price target: $56.
What does Travere Therapeutics, Inc. do?Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved...
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved FILSPARI (sparsentan) for IgAN and a supplemental NDA under review for FSGS (PDUFA April 13, 2026), plus pegtibatinase in pivotal Phase 3 for homocystinuria. Revenue derives from U.S. FILSPARI sales and milestone/royalty payments from out-licensing partners CSL Vifor and Chugai for ex-U.S. territories.